CCAP Stock Recent News

Spring is an ideal time for income investors to revisit portfolios, focusing on quality stocks like Crescent Capital BDC and Federal Realty Trust. Crescent Capital BDC offers a 12.4% yield, strong dividend coverage, and a diversified, conservatively managed portfolio, trading at a 24% discount to NAV. Federal Realty Investment Trust has a 57-year dividend growth streak, high-quality retail assets, and a 4.8% yield, trading well below historical valuation norms.

CCAP experienced a stock price drop of over 10% due to uncertainty about its income potential and value proposition. CCAP's portfolio is 90% first-lien debt, with 85% in non-cyclical industries, ensuring priority in capital collection and defensive positioning. Diversification is key: top 10 investments hold only 15% of the portfolio, with an average position of 0.5% and low non-accruals.

Crescent Capital BDC, Inc. offers a 10.6% dividend yield and trades at an 11% discount to book value, making it a compelling income investment. CCAP's portfolio is conservatively managed with 90% senior secured loans and strong private equity sponsorship, with low non-accruals. Despite lower base rates, CCAP maintains solid returns, supported by a healthy balance sheet and stable NAV/share, with management expecting increased deal activity.

Investors need to pay close attention to Crescent Capital BDC (CCAP) stock based on the movements in the options market lately.

Market volatility underscores the need for income-producing assets; Crescent Capital BDC and Omega Healthcare Investors offer compelling value with strong fundamentals and attractive yields. Crescent Capital BDC carries a diversified portfolio, high-quality secured debt, robust liquidity, and an 11% dividend yield while trading at a 15% discount to NAV. Omega Healthcare Investors benefits from a stable triple-net lease model, improving operator fundamentals, and a 7.3% dividend yield, with potential for capital appreciation.

The essence of financial awareness is to realize that money can work for us through our investments. Understanding the value of money is the first step toward financial education, which leads to the selection of the most appropriate tools for developing that awareness. In my case, the instruments I have adopted are largely high-income vehicles, with monthly and, in some cases, quarterly distribution.

Crescent Capital BDC is downgraded due to a declining NII, and a less attractive discount to NAV. However, I don't see a reason for existing shareholders to sell. Despite recent weaknesses, CCAP maintains a strong dividend yield of 10.4%, supported by a healthy coverage rate and supplemental distributions for the next three quarters. The portfolio's high industry diversification and 90% first lien debt structure provide defensive measures, but higher interest rates challenge borrower performance.

A contrarian mindset can help dividend investors find bargains, with Crescent Capital BDC and Cenovus Energy offering high yields after recent price drops. Crescent Capital BDC carries a diversified debt portfolio, strong dividend coverage, and a safe leverage profile, making it a compelling buy at a 9% discount to book value. Cenovus Energy's integrated operations and cost optimization efforts position it for long-term growth, with plans to return 100% of excess free cash flow to shareholders.

Crescent Capital BDC, Inc. (NASDAQ:CCAP ) Q4 2024 Earnings Conference Call February 20, 2025 ET Company Participants Dan McMahon - Head, IR Jason Breaux - CEO Henry Chung - President Gerhard Lombard - CFO Conference Call Participants Robert Dodd - Raymond James Mickey Schleien - Ladenburg Paul Johnson - KBW Operator Thank you for standing by. My name is Janine, and I will be your lead operator for today's call.

Crescent Capital BDC (CCAP) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.61 per share a year ago.